Southern Illinois University Edwardsville, Ruling No. 2026-15 (2026)

REJECTION OF APPEAL

Southern Illinois University Edwardsville (the University) seeks Departmental Appeals Board review of a decision by the National Institutes of Health (NIH) to terminate a grant issued to the University.  The Board lacks jurisdiction over this matter because the grant termination does not fall within any of the categories of disputes reviewable by the Board under 45 C.F.R. Part 16, Appendix A, or 42 C.F.R. Part 50, Subpart D.  The appealed decision does not represent a disallowance, a termination for failure to comply with the terms of the award, a denial of a noncompeting continuation award for failure to comply with the terms of a previous award, or a voiding.  For the reasons discussed below, this appeal must be rejected.

Legal Background

The Board’s jurisdiction to hear and decide appeals is limited.  Ca. Dep’t of Finance, DAB No. 1592, at 17 (1996) (“[T]here is no general right to review by the Board . . .”).  Board review is available only as provided by statute, regulation, or valid delegation of authority from the Department of Health and Human Services (HHS) Secretary or the head of an HHS operating component.  Experts Are Us, Inc., DAB No. 2342, at 5 (2010); 45 C.F.R. Part 16, App. A, ¶ A.

Before the Board will accept an appeal, the Board’s regulations at 45 C.F.R. Part 16 require that the following conditions be met:  (1) the appellant must have received a “final written decision” by an HHS component (45 C.F.R. § 16.3(b)); (2) the appellant must have appealed that decision within 30 days after receiving it (id.); (3) the appellant must have “exhausted any preliminary review process required by regulation” (id. § 16.3(c)); and (4) the disputed decision “must arise under a program which uses the Board for dispute resolution” and be the type of decision that the Board is authorized to review, as specified in Part 16, Appendix A (id. § 16.3(a); 45 C.F.R. Part 16, App. A, ¶¶ A-E).  The fourth requirement for Board jurisdiction is at issue here.

Page 2

Title 45 C.F.R. Part 16, Appendix A, identifies HHS programs that use the Board for dispute resolution and the types of “final written decisions” reviewable by the Board.  45 C.F.R. Part 16, App. A, ¶ A; see also 46 Fed. Reg. 1644, 1645 (Jan. 6, 1981) (noting that Appendix A is the Board’s “jurisdiction statement” reflecting “disputes which agencies have chosen to submit to the Board”).  The Board is authorized to review certain agency decisions involving grants.  See 45 C.F.R. Part 16, App. A, ¶¶ B, C.  A grant is a type of federal financial assistance that provides support or stimulation to carry out a public purpose as authorized by a law of the United States.  See 2 C.F.R. § 200.1 (defining “federal award,” “federal financial assistance,” and “grant agreement or grant”); 31 U.S.C. § 6304 (grant agreements).  Research grant awards made by NIH are subject to general terms and conditions depending on the type of grant, as well as any special terms and conditions in the notice of award.  See Targazyme, Inc., DAB No. 2939, at 1-2 (2019).  NIH issues a Grants Policy Statement (NIH GPS) to “make available to NIH recipients, in a single document, the policy requirements that serve as the terms and conditions of NIH grant awards.”  NIH GPS at ii.1

As relevant here, Appendix A provides that the Board reviews “the following types of final written decisions in disputes arising in any HHS program authorizing the award of direct, discretionary project grants or cooperative agreements:”

(1) A disallowance or other determination denying payment of an amount claimed under an award, or requiring return or set-off of funds already received.  . . .

(2) A termination for failure to comply with the terms of an award.

(3) A denial of a noncompeting continuation award under the project period system of funding where the denial is for failure to comply with the terms of a previous award.

(4) A voiding (a decision that an award is invalid because it was not authorized by statute or regulation or because it was fraudulently obtained).

45 C.F.R. Part 16, App. A, ¶ C(a)(1)-(4).2

Page 3

When an HHS component, such as NIH, uses a preliminary appeal process, “the ‘final written decision’ for purposes of Board review is the decision issued as a result of that process.”  Id., App. A, ¶ C(b).  One such preliminary appeal process is found at 42 C.F.R. Part 50, Subpart D, which establishes a procedure for resolving certain “grant and cooperative agreement disputes” in programs administered by NIH.  42 C.F.R. §§ 50.401, 50.402.  The preliminary appeal process under Subpart D applies only to certain “adverse determinations under discretionary grants and cooperative agreements,” as specified in section 50.404(a).  Section 50.404(a) mirrors the list of reviewable final written decisions under Part 16, Appendix A, ¶ C(a).3  If a grantee contests an “adverse determination” to which the preliminary appeal process applies, the grantee must exhaust that process before the Board will accept the appeal under Part 16.  42 C.F.R. § 50.403.

The Board Chair determines whether the conditions for Board jurisdiction are satisfied.  See 45 C.F.R. § 16.7(b) (providing that the Board will notify the parties if the Board Chair determines that the appeal does not meet the conditions in section 16.3).

Procedural and Case Background

A.       Grant Termination

By letter dated June 2, 2025, NIH terminated award no. 1R25GM154360-01 pursuant to the 2024 NIH GPS and 2 C.F.R. § 200.340.  Dkt. 4 (initial notice).  The letter states that the NIH GPS, incorporated into all NIH grant awards, permits NIH to terminate awards as outlined in 2 C.F.R. § 200.340.  Id.  The letter further states that, at the time the grant was issued in May 2024, section 200.340(a)(4) authorized federal agencies to terminate grants “‘to the greatest extent authorized by law, if an award no longer effectuates the

Page 4

program goals or agency priorities.’”  Id.4  NIH states that “[t]his project no longer effectuates agency priorities,” and “there is no modification of the project that would align with agency priorities.”  Id.  The letter notes that the University may submit a reconsideration request to NIH if it objects to the termination.  Id. at 2.  The University then submitted a reconsideration request to NIH.

By email dated August 14, 2025, NIH denied the University’s request for reconsideration, stating that it “terminated the project on the grounds that the research activities do not align with NIH/HHS priorities.”  Dkt. 4a (reconsidered decision).  The email states that NIH upheld the termination because “this project supports DEI and does not align with the agency’s priorities.”  Id.  NIH did not assert, either in the initial termination notice or reconsidered decision, that the University failed to comply with the terms of the award.  No appeal rights were offered in the reconsidered decision.

B.       Notice of Appeal

On or about September 15, 2025, the University submitted a notice of appeal (NA) to the Board, requesting review of NIH’s termination decision “in accordance with the provisions of 45 CFR Part 16.”  NA at 1.  The University did not address the Board’s jurisdictional requirements under Part 16 but argued that 2 C.F.R. § 200.340 is “not controlling” and that “NIH lacks authority to terminate the grant under [that] provision.”  Id. 

On September 30, 2025, the Board acknowledged receipt of the notice of appeal but advised the parties that the Chair was “currently evaluating whether the Board has jurisdiction to review the agency decision described in the notice of appeal.”  Dkt. 6.

Analysis

I.        The appeal does not concern a final written decision reviewable by the Board under 45 C.F.R. Part 16, Appendix A.

The Board lacks jurisdiction over this matter because the grant termination does not fall within any of the categories of disputes reviewable by the Board under 45 C.F.R. Part 16, Appendix A.  Although this dispute arises under an “HHS program authorizing the award of direct, discretionary project grants,” the appealed decision is not a disallowance, a termination for failure to comply with the terms of the award, a denial of a noncompeting continuation award for failure to comply with the terms of a previous award, or a voiding.  See 45 C.F.R. Part 16, App. A ¶ C(a)(1)-(4).  The record reflects that NIH terminated the award having determined that it no longer effectuates agency priorities.  See Dkt. 4

Page 5

(initial notice), Dkt. 4a (reconsidered decision).  As the Board previously concluded in several similar cases, we have no authority to review the NIH grant termination at issue.  See, e.g., Clark Atlanta Univ., Ruling No. 2026-8 (Dec. 30, 2025).5

In 2020, the Office of Management and Budget (OMB) issued revised guidance regarding federal award terminations under 2 C.F.R. § 200.340.6  The revised guidance replaced the “for cause” basis for termination with a provision authorizing federal awarding agencies to terminate an award “to the greatest extent authorized by law, if an award no longer effectuates the program goals or agency priorities.”  Compare 2 C.F.R. § 200.339(a)(2) (eff. to Aug. 12, 2020) with 2 C.F.R. § 200.340(a)(2) (eff. Aug. 13, 2020).  OMB stated that it revised section 200.340 “to strengthen the ability of the Federal awarding agency to terminate Federal awards, to the greatest extent authorized by law, when the Federal award no longer effectuates the program goals or Federal awarding agency priorities.”  See 85 Fed. Reg. 49,506, 49,507 (Aug. 13, 2020).  OMB further stated that it was “eliminating the termination for cause provision because this term is not substantially different than the provision allowing Federal awarding agencies to terminate Federal awards when the recipient fails to comply with the terms and conditions.”  Id. at 49,508.  OMB retained, as a separate basis for termination, the awarding agency’s authority to terminate an award if a grantee “fails to comply with the terms and conditions” of the award.  Compare 2 C.F.R. § 200.339(a)(1) (eff. to Aug. 12, 2020) with 2 C.F.R. § 200.340(a)(1) (eff. Aug. 13, 2020).7  As further explained below, NIH made section 200.340 applicable to NIH grants through the NIH GPS.8  HHS, however, has not amended Part 16, Appendix A, or issued other regulations authorizing the Board to review a grant termination based on an awarding agency’s determination that an award no longer effectuates program goals or agency priorities.

Page 6

The University argues that the termination provisions at 2 C.F.R. § 200.340 were not adopted by HHS until October 2024 and did not become effective until October 2025.  NA at 1.  According to the University, at the time of the award termination, NIH could only terminate an award (i) for non-compliance with award terms or conditions, (ii) for cause, or (iii) with the consent of the awardee.  Id. (referencing HHS-specific regulations at 45 C.F.R. § 75.372(a)).  The University points out that NIH did not rely on any of those grounds as a basis for terminating the award.

We agree that NIH did not terminate the award for noncompliance with its terms or conditions, for cause, or with the University’s consent.  NIH stated in the initial notice that the award was terminated pursuant to the NIH GPS and 2 C.F.R. § 200.340 because the award “no longer effectuates agency priorities.”  Dkt. 4.  Similarly, the reconsidered decision upheld the award termination on grounds that “the research activities do not align with NIH/HHS priorities.”  Dkt. 4a.

NIH relied on the termination authority in the NIH GPS, which is part of the standard terms and conditions of all NIH awards.  See NIH GPS at IIA-1 (§ 3) (“Part II includes the terms and conditions of NIH grants and cooperative agreements and is incorporated by reference in all NIH grant and cooperative agreement awards.”); see also Targazyme at 1-2.  NIH GPS § 8.5.2 provides:

If a recipient has failed to comply with the terms and conditions of award, NIH may take one or more enforcement actions which include disallowing costs, withholding of further awards, or wholly or partly suspending the grant, pending corrective action.  NIH may also terminate the grant in whole or in part as outlined in 2 CFR Part 200.340.

NIH GPS at IIA-155 (emphasis added).  Thus, the notion that NIH could only terminate an award based on HHS-specific regulations is belied by the language of the NIH GPS.

Moreover, the University is conflating the jurisdictional question with a different one:  whether NIH had the legal authority to terminate the award under section 200.340 based on a change in agency priorities.  The question of Board jurisdiction, however, does not turn on whether NIH lawfully terminated the grant due to a change in agency priorities or whether NIH lawfully incorporated 2 C.F.R. § 200.340 into the NIH GPS before its adoption by HHS.  Those questions go to the merits of the dispute.  The question for purposes of determining jurisdiction, and the only issue decided here, is whether the challenged decision is the type of final written agency decision reviewable by the Board under 45 C.F.R. Part 16, Appendix A.

With respect to discretionary grants, the Board may review a final agency decision terminating an award “for failure to comply with the terms of [the] award.”  45 C.F.R. Part 16, App. A, ¶ C(a)(2).  The Board is not authorized under Part 16, Appendix A to

Page 7

review other types of terminations arising under direct, discretionary project grants.  Cf. Dignity, LLC, DAB No. 3121, at 22-23 (2023) (holding that the Board has no authority under Appendix A to review an agency decision denying a non-competing continuation award, except to the extent that the denial is based on the grantee’s failure to comply with the terms and conditions of the prior award).  Again, to obtain Board review of a final agency decision, all regulatory conditions for review must be satisfied, including the requirement that the appealed decision be reviewable under Part 16, Appendix A.  See 45 C.F.R. § 16.3; see also Dignity at 22-23.  That requirement is not satisfied here.

Finally, Appendix A states that “[d]isputes under programs not specified in this appendix” may be reviewed by the Board if such review is authorized by a “program regulation” or “memorandum of understanding between the Board and the head of the appropriate HHS operating component or other agency responsible for administering the program.”  45 C.F.R. Part 16, App. A, ¶ A.  However, no program regulation or memorandum of understanding authorizes the Board to review disputes concerning NIH grant terminations based on the agency’s determination that an award no longer effectuates or aligns with “agency priorities.”

II.      NIH’s preliminary appeal process under 42 C.F.R. Part 50, Subpart D is inapplicable.

The appeal process under Subpart D applies to certain “adverse determinations” under discretionary project grants, none of which apply here.  See 42 C.F.R. § 50.404(a)(1)-(4).  The appealed decision is not a termination for failure to comply with the terms of the award, a disallowance of an expenditure charged to the grant or failure to account for grant funds, a determination that a grant is void, or a denial of a noncompeting continuation award for failure to comply with the terms of a previous award.  See id.  Thus, for the same reasons that the grant termination is not reviewable by the Board under 45 C.F.R. Part 16, Appendix A, ¶ C, it is not subject to the preliminary appeal process under 42 C.F.R. Part 50, Subpart D.

Conclusion

The Board’s jurisdiction is limited, and no statute, regulation, or delegation of authority confers the Board with jurisdiction to review this matter.  I therefore reject the University’s appeal for lack of jurisdiction.